Yungjin Pharm. Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public, Subsidiary
- Established
- 1962-07-16
- Employees
- 624
- Market Cap
- -
- Website
- http://www.yungjin.co.kr
Clinical Trials
12
Active:0
Completed:11
Trial Phases
3 Phases
Phase 1:7
Phase 2:4
Phase 4:1
Drug Approvals
7
PHILIPPINES:7
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (58.3%)Phase 2
4 (33.3%)Phase 4
1 (8.3%)A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Yungjin Pharm. Co., Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT04703868
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Daehak-ro Jongno-gu, Korea, Republic of
A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: YRA-1909 low doseDrug: YRA-1909 mid doseDrug: YRA-1909 high doseDrug: Placebo
- First Posted Date
- 2017-09-07
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Yungjin Pharm. Co., Ltd.
- Target Recruit Count
- 116
- Registration Number
- NCT03275025
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
🇰🇷Hanllym University Medical Center, Anyang, Korea, Republic of
🇰🇷Chungbuk National University Hospital, Chungju, Korea, Republic of
Evaluate the Pharmacokinetic Characteristics and Safety/Tolerability of YNP-1807 Compared to Lyrica® After Oral Administration Adult Volunteers
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Yungjin Pharm. Co., Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT03261427
- Locations
- 🇰🇷
Severance Hospital, Seoul, Yonsei-ro Seodaemun-gu, Korea, Republic of
Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- MELAS SyndromeMitochondrial Respiratory Chain Deficiencies
- Interventions
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2018-04-27
- Lead Sponsor
- Yungjin Pharm. Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03056209
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Metabolic Syndrome
- Interventions
- Drug: MB12066 200mgDrug: Placebo
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2017-12-21
- Lead Sponsor
- Yungjin Pharm. Co., Ltd.
- Target Recruit Count
- 11
- Registration Number
- NCT02338856
- Locations
- 🇰🇷
Kyungpook National University Hospital, Daegu, Dongduck-ro, Jung-gu, Korea, Republic of
- Prev
- 1
- 2
- 3
- Next
News
No news found